Melatonin concentrations in serum of primary glaucoma patients

Xiao-Ping Ma¹, Man-Yi Shen¹, Guang-Lin Shen¹, Qiao-Ran Qi¹, Xing-Huai Sun²

¹Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
²Department of Ophthalmology, Eye & Ent Hospital of Fudan University, Shanghai 200031, China

Co-first authors: Xiao-Ping Ma and Man-Yi Shen
Correspondence to: Xing-Huai Sun. Department of Ophthalmology, Eye & Ent Hospital of Fudan University, No. 83 Fenyang Road, Xuhui District, Shanghai 200031, China
xhsun@shmu.edu.cn

Keywords: glaucoma; melatonin; circadian rhythm; sleep disorder; anxiety; depression
DOI:10.18240/ijo.2018.08.14
Citation: Ma XP, Shen MY, Shen GL, Qi QR, Sun XH. Melatonin concentrations in serum of primary glaucoma patients. Int J Ophthalmol 2018;11(8):1337-1341

INTRODUCTION

Melatonin (5-methoxy N-acetyltryptamine) is a neurohormone secreted from the pineal gland in human beings, which has a circadian rhythm in its secretion to the blood flow. It has been reported that melatonin and some of its derivatives produce a marked reduction in intraocular pressure (IOP) in normotensive and hypertensive conditions through melatonin receptors[1-3]. In addition, melatonin protects ocular tissue against free radicals which always lead to an extensive loss of the retinal ganglion cells[4-5].

Glucoma is a common, pathophysiologically heterogeneous, progressive optic neuropathy. Elevated IOP together with excessive retinal oxidative stress (ROS) are considered as the main risk factors in the developing of glaucoma, leading to glaucomatous alterations and neurodegeneration[6]. Taking into account the benefits melatonin have to the human eye, we may propose a hypothesis that dysfunctional melatonin signaling may be considered a possible risk factor in the pathogenesis of glaucoma[7]. Rosen et al[7] reported that age-related macular degeneration (AMD), in which cumulative oxidative stress plays an important role, interfered in the production of melatonin. But the changes of circulatory melatonin level in glaucoma have not been reported previously.

Furthermore, it has been reported that patients with different degrees of blindness resulting from glaucoma show abnormal circadian rhythms, along with sleep disturbances and depressed moods[8]. Recently, there has been evidence that alterations in the secretory pattern of melatonin is present in various psychiatric disorders. Rahman et al[9] demonstrated a significant sleep-wake cycle disruption in low melatonin secretors. In the study by Crasson et al[10], the patients with major depression showed a 77min peak time delay of serum melatonin secretion. Considering the possible pathophysiological connection glaucoma has to sleep disorders, anxiety and depression, this may indicate that the nature of melatonin secretion rhythm in glaucoma be disturbed.

Abstract

AIM: To determine whether glaucoma patients exhibit an abnormal melatonin concentration in serum and the effects of psychiatric disorders caused by glaucoma in melatonin secretion.

METHODS: A sample of 80 primary angle-closure glaucoma (PACG) patients, 120 primary open angle glaucoma (POAG) patients, and 120 normal controls were enrolled in this study. All the participants were asked to complete the following questionnaires: Pittsburgh sleep quality index (PSQI), self-rating anxiety scale (SAS), and self-rating depression scale (SDS). Variance analysis was used to compare the subscores between the groups. After that, we chose 58 patients with primary glaucoma and 20 non-glaucoma control patients to collect their serum samples at 7-10 a.m. Serum melatonin levels were measured using enzyme linked immunosorbent assay (ELISA).

RESULTS: Of all participants, the scores of PSQI, SAS, and SDS in PACG and POAG group were 9.38±0.40, 46.08±8.99, 51.1±10.72 and 7.43±0.35, 45.42±9.87, 49.04±12.24 respectively, significantly higher than those in control group (4.16±0.28, 35.49±9.18, 40.31±13.08). The serum melatonin levels in PACG (37.29±2.99 pg/mL) and POAG (35.97±3.64 pg/mL) were significantly higher than the controls (29.96±3.94 pg/mL) (P<0.001). But no difference was found between the PACG and POAG (P=0.216). Glaucoma patients with sleep disorders, anxiety and depression were more likely resulting in the increase of melatonin levels.

CONCLUSION: There is a significant increase in serum melatonin levels in glaucoma patients compared to the controls especially in glaucoma patients with psychiatric disorders such as sleep disorders, anxiety and depression.
In the present study, we tested the hypothesis individuals with primary glaucoma show higher rates of sleep disturbance, anxiety and depression, as compared with a non-glaucoma control group. Serum melatonin was measured to determine whether alterations in the secretory pattern of melatonin are present in glaucoma patients with various psychiatric disorders.

**SUBJECTS AND METHODS**

**Subjects** This was a prospective case-control study conducted from March 2014 to February 2015. In this study, 80 patients with primary angle-closure glaucoma (PACG) and 120 patients with primary open angle glaucoma (POAG) were recruited consecutively in the Eye and ENT Hospital of Fudan University, which is one of the largest eye care hospitals in China. All participants underwent a comprehensive ophthalmologic examination including review of medical history, visual acuity, IOP measurement, gonioscopy, dilated fundoscopy examination. PACG is a chronic progressive optic neuropathy that trabecular obstruction by the peripheral iris has occurred, while the anterior chamber angle of POAG shown to be open on gonioscopy. A control group of 120 healthy subjects without family history of glaucoma or high IOP were recruited from the same area. Participants exclusion criteria included: 1) any kind of intraocular surgery or laser treatment within the last three months; 2) personal history of any other ocular disease such as retinitis pigmentosa; 3) systemic diseases including psychiatric illness; 4) drug or alcohol abuse; 5) pregnancy or lactation; 6) night work or transmeridian travel in the previous three months, that might affect the results. All patients and control participants gave informed consent prior to participation. The study was conducted under Human Research Ethics Committee approval and conformed to the tenets of the Declaration of Helsinki.

**Methods**

**Psychometric measures** Participants were asked to complete a battery of questionnaires independently which included measures of subjective levels of sleepiness, anxiety and depression. Sleep quality of each subject in the three groups (POAG group, PACG group and control group) was measured with the Pittsburgh sleep quality index (PSQI), self-rating anxiety scale (SAS) and self-rating depression scale (SDS) were applied to assess anxiety and depression consecutively. The time required to finish each questionnaire was strictly limited <10min for PSQI, SAS and SDS, respectively. Sleep was considered to be disturbed if the global PSQI score was higher than 7. SAS total score >45 was predefined as cut-off score for anxiety and SDS total score >50 was predefined as cut-off score for depression, as suggested in earlier literature. Scores of PSQI, SAS and SDS were compared between the three groups.

**Melatonin assessment** After psychometric measures, we chose 58 patients with primary glaucoma and 20 non-glaucoma control patients to collect their serum samples at 7-10 a.m. (background light intensity <2 lx, participants were allowed to sleep from 23:00 to 06:00). For measure of serum melatonin, blood samples of 5 mL were drawn from forearm vein and centrifuged immediately. Serum samples (2 mL) were frozen at -70°C until enzyme linked immunosorbent assay (ELISA). This is a competitive immunoassay that determined the melatonin levels by use of a melatonin ELISA kit (LSBioTM Melatonin EIA Competition ELISA Kit America) and an ELISA reader (thermo multiskan FC). Serum melatonin levels are given in pg/mL. We compared melatonin levels in POAG, PACG and control groups and analyzed the disturbance of melatonin levels in glaucoma patients with sleep disorders, anxiety and depression.

**Statistical Analysis** Statistical analyses were performed by using SPSS 20.0 software. Continuous variables were expressed as means±standard deviation and analyzed by using the non-parametric Wilcoxon ranked test and one-way ANOVA. While categorical variables were presented as percentage, they were assessed by mean of the Pearson’s Chi-squared test ($\chi^2$). $P<0.05$ considered statistically significant.

**RESULTS**

Eventually, 80 PACG patients, 120 POAG patients and 120 controls with a complete questionnaire were included. Demographic details of recruited patients were shown in Table 1. The scores of PSQI, SAS and SDS were higher in glaucoma patients than in controls, whereas the PACG group had a higher score for all scales (9.38±0.40; 46.08±8.99; 51.11±10.72) than the POAG group (7.43±0.35; 45.42±9.87; 49.04±12.24) and control group (4.16±0.28; 35.49±9.18; 40.31±13.08) (Table 2). Taking PSQI score >7, SAS score >45 and SDS score >50 as cut-off, the prevalence of sleep disorder, anxiety and depression in the PACG group was significantly higher than in the POAG group (54.2%, 56.2%, 51.2%) was significantly higher than in the POAG group (54.2%, P=0.000; 50.0%, P=0.000; 53.3%, P=0.000) and control group (17.5%, P=0.000; 21.7%, P=0.000; 25.8%, P=0.000) (Table 2). There were 58 patients in the glaucoma group and...
Table 4 Comparison of melatonin levels in glaucoma patients with psychiatric disorders and the control group

<table>
<thead>
<tr>
<th>Parameters</th>
<th>PACG (n=80)</th>
<th>POAG (n=120)</th>
<th>Control (n=120)</th>
<th>P</th>
<th>*P</th>
<th>**P</th>
<th>***P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleep disturbance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep disturbance, anxiety</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep disturbance, anxiety</td>
<td>80.0%</td>
<td>54.2%</td>
<td>17.5%</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.839</td>
</tr>
<tr>
<td>Anxiety</td>
<td>56.2%</td>
<td>50.0%</td>
<td>21.7%</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.386</td>
</tr>
<tr>
<td>Depression</td>
<td>51.2%</td>
<td>53.3%</td>
<td>25.8%</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.084</td>
</tr>
</tbody>
</table>

PACG: Primary angle-closure glaucoma; POAG: Primary open angle glaucoma; PSQI: Pittsburgh sleep quality index; SAS: Self-rating anxiety scale; SDS: Self-rating depression scale. *PACG versus control; **POAG versus control; ***PACG versus POAG. Kruskal-Wallis test followed by all pairwise multiple comparisons.

Table 3 Demographic data and melatonin levels in patients with glaucoma and normal controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>PACG (n=16)</th>
<th>POAG (n=42)</th>
<th>Control (n=20)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>59.4±8.01</td>
<td>53.2±6.27</td>
<td>53.2±6.27</td>
<td>0.00</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>4/12</td>
<td>7/13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melatonin (pg/mL)</td>
<td>37.29±2.99</td>
<td>35.97±3.64</td>
<td>29.96±3.94</td>
<td>0.00</td>
</tr>
</tbody>
</table>

*POAG vs control; **PACG vs control.

Table 4 Comparison of melatonin levels in glaucoma patients with psychiatric disorders and the control group

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GPD (n=20)</th>
<th>GPWD (n=38)</th>
<th>GPA (n=20)</th>
<th>GPWA (n=38)</th>
<th>GPD (n=27)</th>
<th>GPWSD (n=31)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57.4±6.91</td>
<td>55.1±8.73</td>
<td>55.9±6.02</td>
<td>55.9±9.17</td>
<td>55.2±8.64</td>
<td>56.4±7.84</td>
<td>0.67</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>8/12</td>
<td>23/15</td>
<td>6/14</td>
<td>10/28</td>
<td>9/18</td>
<td>7/24</td>
<td>0.36</td>
</tr>
<tr>
<td>IOP of the worse eye</td>
<td>22.85±5.54</td>
<td>22.21±3.44</td>
<td>23.4±4.69</td>
<td>21.9±3.96</td>
<td>23.9±4.97</td>
<td>21.2±3.03</td>
<td>0.03</td>
</tr>
<tr>
<td>Melatonin (pg/mL)</td>
<td>38.34±2.67</td>
<td>35.28±3.45</td>
<td>37.95±3.57</td>
<td>35.48±3.19</td>
<td>38.05±2.65</td>
<td>34.84±3.50</td>
<td>0.00</td>
</tr>
</tbody>
</table>

GPD: Glaucoma patients with depression; GPWD: Glaucoma patients without depression; GPA: Glaucoma patients with anxiety; GPWA: Glaucoma patients without anxiety; GPSD: Glaucoma patients with sleep disturbance; GPWSD: Glaucoma patients without sleep disturbance; PACG: Primary angle-closure glaucoma; POAG: Primary open angle glaucoma.

DISCUSSION

The rhythm of melatonin secretion from the pineal gland, increasing during the evening and returning to its baseline levels at about 10 a.m., is driven by a “biological clock” in the suprachiasmatic nucleus (SCN) of the hypothalamus. According to the circadian disruption hypothesis, light intensity and certain critical wave lengths might disrupt the endogenous circadian rhythm and specifically suppress production of the pineal hormone melatonin and its secretion into the blood via a specific pathway. Retinal stimulation by light sends a stimulatory signal to the SCN which in turn transmits the signal indirectly to pinealocytes regulating the pineal melatonin secretion. It has been reported that daily illumination, ophthalmic factors, sleep duration, and race each had independent associations with acrophases of melatonin excretion.
Effects of glaucoma on melatonin secretion

In our study, results showed melatonin concentrations of glaucoma patients especially those with psychiatric disorders increased at 7-10 a.m., and suggested that the effects of glaucoma on the rhythm of melatonin secretion can be two-fold: 1) affecting the photic input to the circadian system; 2) a direct impact of sleep disorders, anxiety and depression relating to glaucoma.

Glaucoma is an ocular degenerative disease with a progressive death of the retinal ganglion cells and eventually causes optic nerve atrophy by way of axonal loss. Intrinsically photosensitive retinal ganglion cells (ipRGC), a specialized subset of retinal ganglion cells, play a major role in phototransduction through the retinohypothalamic tract to the SCN and herewith also in the regulation of the pineal melatonin secretion\[6\]. ipRGC death leads to direct and adverse effects on the circadian timing system as well as disruption of melatonin secretion. Furthermore, reduced axonal number would have a relative diminution of transmitted stimuli and reduced axonal stimulation to the central visual pathways likely diminishes light input to the circadian system, affecting the rhythm of pineal melatonin production\[12\].

In addition, melatonin levels in patients with PACG are higher than that in POAG. Acute IOP elevation in some of the PACG patients leads to ischemic-reperfusion damage to the whole retina, including not only the ganglion cells, but also other neurons like rods and cones\[14\]. Therefore, in PACG, the residual ipRGCs may get less input from the residual rods and cons, resulting in less photic input to circadian system and increase of melatonin concentrations. However, there’s not much distance of melatonin level between 37.29±2.99 and 35.97±3.64 pg/mL, which might be attributed to no statistically significant IOP and statistically speaking, more studies are needed.

The patients in glaucoma group were older as compared to control group which might relate to the increase of serum melatonin level as well. The effects of age on the melatonin secretion rhythm might be wide-ranging, as 1) ophthalmic factors associated with increasing age such as senile miosis and opacification of the ocular lens reduce light transmission to the retina, eventually affect retinal stimulation to SCN and melatonin secretion; 2) age-related reduction in light responsivity leads to that it might be inadequate to prevent circadian misalignment with an average amount of illumination for the elderly, resulting in a disturbance of melatonin secretion; 3) normal individuals losing ganglion cells in an age-dependent manner at an estimated rate as high as 5000 axons per year\[19\], together with neurodegenerative changes with age in the SCN may cause decreased regulation function of pineal melatonin secretion.

On the basis of aforementioned analysis, glaucoma is an ophthalmological disease affecting the photic input to the circadian system and leading to circadian rhythm alteration and melatonin production impairment. On the other hand, there has been evidence that glaucoma leads to a high incidence of sleep disorders, anxiety and depression as well as a dysregulation of circadian rhythms\[13\]. In the present study, we used self-reporting questionnaires to investigate the prevalence of disturbed sleep, anxiety, and depression among glaucoma patients. As compared with 17.5% of the control patients, 80% of PACG patients and 54.2% of POAG patients had a PSQI total score indicating clinically relevant sleep disturbance. Our study showed significant differences concerning different PSQI scores which could partly be caused by a circadian misalignment. Regarding anxiety in glaucoma patients, this study showed higher SAS scores among patients with glaucoma, as compared with the control group. In the whole sample, 21.7% of the control patients reached SDS scores above the predefined cut-off, whereas this percentage was 51.2% for PACG and 53.3% for POAG. Our results are in concordance with those of Mabuchi et al\[16\] who found a higher prevalence of anxiety and depression among glaucoma patients. Wang and colleagues have found that the ratio of POAG patients with sleep disorders grew with the aggravation of the impairment of visual field, but the differences were not statistically significant\[14\].

Considering the melatonin secretion are altered in patients suffering from both disturbed sleep as well as in patients suffering from major depressive disorder, the disturbances of melatonin rhythm could be related to the comorbid depression and sleep disorder in glaucoma patients\[17,18\]. We measured serum melatonin levels in glaucoma patients with or without psychiatric diseases and found that in patients with sleep disorders, anxiety or depression, the mean serum melatonin level was significantly higher. We evidently determined that the increase of melatonin secretion in glaucoma patients related to the sleep disorders, anxiety and depression. Increased melatonin level of patients with psychiatric problem might be explained by the reduction of the photic input to the circadian system as a result of less opportunity for exposure to bright light exposure. Furthermore, stress reaction caused by psychiatric disorders may lead to oxidative damage in retinal which also resulted in the death of ipRGCs and abnormal melatonin secretion\[19\].

Limitations Our study has some limitations that deserve comment. First, we did not limit the social factors such as profession which may affect the circadian rhythm. The second limitation is the use of self-rating scales to assess sleep symptoms, anxiety and depression. Although all scales used in the current study are widely employed in research and have been chosen because of their clinical validity and reliability, a more objective index may be warranted to test the psychiatric disorders of glaucoma patients and a psychiatrist is needed to
make the right diagnosis. The third limitation is that we did not analyze cup disc ratio and visual field defects in glaucoma patients and perform the glaucoma grading. Correlation analysis may help reveal association between glaucoma severity and psychiatric disorders and give further assessment of the influence of glaucoma on melatonin secretion.

There is a relatively high prevalence of sleep disturbance, anxiety and depression among glaucoma patients. At present, standard ophthalmological care for glaucoma consists mainly of the management of IOP. Considering higher comorbid levels of sleep disorders, anxiety and depression can be assumed for glaucoma patients, an additional psychiatric assessment and treatment are needed in glaucoma patients. Nevertheless, further studies are needed in order to discover a better solution for treating psychiatric disorders which in turn, have positive results in relieving the progression of glaucoma.

ACKNOWLEDGEMENTS

Conflicts of Interest: Ma XP, None; Shen MY, None; Shen GL, None; Qi QR, None; Sun XH, None.

REFERENCES


